This year, the U.S. Department of Justice will likely leverage the False Claims Act to ramp up health and life sciences enforcement efforts involving cybersecurity, the COVID-19 provider relief fund and private equity investors, and a number of significant FCA theories will likely be tested in courts, say attorneys at Epstein Becker.